PEMFEXY® (pemetrexed injection)
PEMFEXY is indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
COPAY AND FINANCIAL ASSISTANCE – PEMFEXY® (pemetrexed …
The PEMFEXY® Copay Assistance Program is for commercially insured, eligible patients whose insurance does not cover the full cost of their PEMFEXY® treatment. Learn more about eligibility requirements in the Terms and Conditions. COPAY PROGRAM DETAILS FOR …
PEMFEXY™ is a folate analog metabolic inhibitor indicated for: • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no
PEMFEXY is a folate analog metabolic inhibitor indicated for: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC. (1.1)
first-line chemotherapy. PEMFEXY is indicated as a single agent for the treatment of patients with recurrent, metastatic non-squamous non-small cell lung cancer (NSCLC) fter prior chemotherapy. Limitation of Use: PEMFEXY is not indicated for the treatment of patients with squamous cell no.
Benefits with EAGLE CAN Care & Access Network Enrollment form: Benefit Verification for BELRAPZO® or PEMFEXY®. Referral to the Patient Assistance Program (PAP) when applicable* and/or. Commercial Copay Assistance Program for PEMFEXY® ONLY. Patient and/or Advocate Checklist for Benefit Verification, or PEMFEXY Copay Assistance:
Infusion Time: Administer PEMFEXY™ as an intravenous infusion over 10 minutes. Storage: Store unopened vial refrigerated at 2°C to 8°C (36°F to 46°F). Store diluted PEMFEXY™ refrigerated at 2°C to 8°C (36 °F to 46°F) or at ambient room temperature and room lighting for no more than 48 hours.
PEMFEXY is indicated as a single agent for the treatment of patients with recurrent, metastatic non-squamous non- small cell lung cancer (NSCLC) after prior chemotherapy.
PEMFEXY™ is a folate analog metabolic inhibitor indicated for: • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer
BELRAPZO (bendamustine hydrochloride injection) PEMFEXY™ (pemetrexed injection) Product NDC: Previous Therapies, if any Concurrent Therapies, if any Site of Care* ATTESTATIONS AND SIGNATURES Prescriber Attestation: I confirm that I have prescribed the Eagle product identified above as an appropriate treatment for this Patient.